CRISPR-gene drive safely kills mosquitos
A new gene drive can cause the complete collapse of caged malaria-carrying mosquito populations, researchers from Imperial College report in Nature Biotechnology.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
Entries by Thomas Gabrielczyk
ROBOX makes storable CYPs
CYPs have a number of disadvantages, including low stability or inactivity. The Austrian Centre of Industrial Biotechnology (acib), together with an consortium within the EU-project ROBOX, created lyophilised CYP biocatalysts that have proven to be very promising for a variety of industrial applications for the pharma, flavour and fragrance, and material science industries.
Managing complexity to bring drugs to clinic faster
Integrating the disparate stages of drug development is the most time and cost-efficient way of turning a promising candidate compound into a pharmaceutical product. A CDMO that offers coordinated end-to-end services simplifies oversight.
CHMP with new Chair – 13 meds recommended
The CHMP elected Harald Enzmann as its new Chair on Friday, and recommended thirteen medicines for approval, three thereof orphan medicines.
European biotech companies enter IPO prep course
European stock exchange operator Euronext kicked off its fourth annual capital markets training programme for non-listed companies – this time also including companies from Germany, Italy, Spain, and Switzerland.
Novo Nordisk reveals details about its R&D transformation
Novo Nordisk A/S (NOVOB:DC) said it plans to restructure its entire Research & Development (R&D) organization. Consequently, the company will lay off 400 employees from R&D roles in Denmark and China.
Pharming receives complete response letter from FDA
The FDA has requested additional clincal data demonstrating that Pharming Group’s recombinant C1 esterase blocker Ruconest can prevent hereditary angioedema attacks (HAE).
CRISPR Therapeutics and Viacyte launch diabetes partnership
CRISPR Therapeutics AG announced a development partnership with ViaCyte Inc to develop genome-edited pancreatic islet cells, which do not require immunosuppression, to treat diabetes.
Sanofi preparing label extension for dupilumab
Positive Phase 3 results with Sanofi/Regeneron‘s IL4/IL-13-targeting antibody dupilumab (Dupixent) in adolescents with moderate-to-severe atopic dermatitis will form the basis of a regulatory submission in this new patient population, according to announcements of Sanofi.
Calcium does not contribute to heart failure
Slowing the leak of Calcium leak into cardiomyocytes does not improve the pumping malfunction in heart failure, German cardiologists report in Science Translational Medicine.